Roche touts long-term data of Perjeta combination therapy for breast cancer - Seeking Alpha

Retrieved on: 2022-07-14 19:14:47

Tags for this article:

Click the tags to see associated articles and topics

Roche touts long-term data of Perjeta combination therapy for breast cancer - Seeking Alpha. View article details on hiswai:

Excerpt

A combination of Roche's (RHHBY) Perjeta (pertuzumab) and Herceptin (trastuzumab) along chemotherapy bested Herceptin and chemotherapy alone over ...

Article found on: seekingalpha.com